• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

The Future of Multiple Myeloma Treatment

Opinion
Video

Experts discuss the evolving landscape of multiple myeloma treatment, exploring real-world evidence's role in shaping the future and its impact on clinical decisions, rare subgroups, and treatment sequencing.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions and subtitles off, selected

      This is a video synopsis/summary of a Peer Exchange featuring Joshua Richter, MD; Rafat Abonour, MD; Faith Davies, MD; and Amrita Krishnan, MD.

      In this forward-looking discussion on the future of myeloma treatment, Abonour emphasizes the distinction between real-world data and real-world evidence, emphasizing the improvement in data quality over the years. Richter envisions a transformation where large registries, incorporating electronic medical records and patient-reported surveys, become essential for generating real-world evidence. Davies highlights the potential to study quality-of-life impacts and address data gaps, especially in rare subgroups and treatment sequencing. The conversation underscores the importance of educating colleagues on the scientific validity of real-world evidence and its potential to address critical questions in myeloma treatment.

      Video synopsis is AI-generated and reviewed by AJMC® editorial staff.

      © 2025 MJH Life Sciences
      AJMC®
      All rights reserved.